title: Mismatch repair deficiency predicts benefit of anti-PD-1 therapy.
authors.forename: Esther
authors.initials: E
authors.lastname: Lau
mesh_terms: D005260:Female; D006801:Humans; D008297:Male; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D015179:Colorectal Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000401:mortality / Q000473:pathology; D016001:Confidence Intervals; D018572:Disease-Free Survival; D053843:DNA Mismatch Repair / Q000187:drug effects / Q000235:genetics; D004334:Drug Administration Schedule; D007262:Infusions, Intravenous; D053208:Kaplan-Meier Estimate; D058990:Molecular Targeted Therapy / Q000379:methods; D009361:Neoplasm Invasiveness / Q000473:pathology; D011237:Predictive Value of Tests; D061026:Programmed Cell Death 1 Receptor / Q000187:drug effects / Q000235:genetics; D018570:Risk Assessment; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; C105992:PDCD1 protein, human; C582435:pembrolizumab; D061026:Programmed Cell Death 1 Receptor